NGEN (NervGen Pharma) Stock Based Compensation: $3.88 Mil (TTM As of Mar. 2026)


NGEN NervGen Pharma Corp NGEN
22 GF Score
Price $2.10
! 2 Warning Signs
View Full Analysis

What is NervGen Pharma Stock Based Compensation?

NervGen Pharma NGEN +1.44% 22 Stock Based Compensation is $3.88 Mil as of Mar. 2026. GuruFocus rates NGEN with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

NervGen Pharma's Stock Based Compensation for the three months ended in Mar. 2026 was $0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $3.88 Mil.

NervGen Pharma Stock Based Compensation Related Terms

NervGen Pharma Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for NervGen Pharma's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NervGen Pharma Stock Based Compensation Chart

NervGen Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only 3.14 2.04 4.51 4.24 3.91

NervGen Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.02 1.48 0.80 0.58 0.00
NGEN
22GF Score
NervGen Pharma Corp NGEN
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NervGen Pharma Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.88 Mil.

What does a Stock Based Compensation of $3.88 Mil mean?
NervGen Pharma (NGEN) has a Stock Based Compensation of $3.88 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for NervGen Pharma and its competitors.
Is NervGen Pharma's Stock Based Compensation too high?
NervGen Pharma's current Stock Based Compensation is $3.88 Mil. Overall, NervGen Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does NervGen Pharma's Stock Based Compensation compare to NKTX and UNCY?
NervGen Pharma's Stock Based Compensation of $3.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for NervGen Pharma and its competitors. NervGen Pharma's current Stock Based Compensation is $3.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NervGen Pharma stock overvalued right now?
NervGen Pharma (NGEN) has a current Stock Based Compensation of $3.88 Mil. The current Stock Based Compensation is $3.88 Mil. NervGen Pharma's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For NervGen Pharma (NGEN), the current Stock Based Compensation is $3.88 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NervGen Pharma Business Description

Other Exchanges 9UA:Germany
Address 112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
22GF Score

Get the complete analysis for NGEN

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.10
Price